LLY vs ABBV: Eli Lilly vs AbbVie Stock Comparison: AI Score, Valuation, Performance and Upside
Eli Lilly is the GLP-1 growth juggernaut with the fastest-growing drug franchise in pharma history and massive obesity market expansion potential. AbbVie is a diversified pharma company navigating the Humira-to-Skyrizi/Rinvoq transition with a high dividend yield and broader therapeutic area exposure. Lilly has superior growth; AbbVie has better income and diversification.
Use this LLY vs ABBV comparison to evaluate two pharma investment approaches. Eli Lilly offers concentrated GLP-1/obesity growth at a premium valuation; AbbVie offers diversified pharma income with strong immunology growth at a more moderate valuation.
LLY holds the edge across 4 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+59.53% vs +20.16%), though ABBV has the better forward P/E setup (15.79x vs 24.87x for LLY). LLY leads on both revenue growth (47.70%) and operating margin (54.22%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for LLY (+11.96%) than for ABBV (+7.85%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to the GLP-1/obesity megatrend through the market-leading tirzepatide franchise
- Believe the obesity drug market TAM is large enough to justify Eli Lilly's premium valuation
- Value Lilly's pipeline optionality in Alzheimer's, oncology, and next-generation oral GLP-1 formulations
- Are comfortable with a growth-stock valuation for a pharmaceutical company
- Prefer a diversified pharma company with exposure across immunology, aesthetics, neuroscience, and oncology
- Value AbbVie's high dividend yield and Dividend Aristocrat status for income-oriented portfolios
- Believe Skyrizi and Rinvoq can fully replace and exceed Humira revenue over the next several years
- Want pharma exposure at a more moderate valuation with better near-term income generation
| Metric | LLY | ABBV |
|---|---|---|
| AI scorei | 76.4 | 53.0 |
| AI ranki | #20 | #316 |
| Latest closei | $1,183.46 | $264.34 |
| 1M returni | -0.50% | +0.55% |
| 6M returni | +34.75% | +26.24% |
| 1Y returni | +59.53% | +20.16% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | ABBV |
|---|---|---|
| 1Y ago | $16.56K (+65.6%) started 2025-09-25 | $12.1K (+21.0%) started 2025-09-25 |
| 5Y ago | $56.3K (+463.0%) started 2021-09-27 | $33.11K (+231.1%) started 2021-09-27 |
| 10Y ago | $202.33K (+1923.3%) started 2016-09-26 | $93.5K (+835.0%) started 2016-09-26 |
Hypothetical — past performance does not guarantee future results.
| Metric | LLY | ABBV |
|---|---|---|
| Market capi | $1.05T | $454.36B |
| Trailing P/Ei | 39.36 | 72.43 |
| Forward P/Ei | 24.87 | 15.79 |
| Price/Salesi | 14.10 | 5.85 |
| EV/Revenuei | 13.72 | 8.06 |
| Analyst targeti | $1,315.04 | $277.31 |
| Target upsidei | +11.96% | +7.85% |
| Metric | LLY | ABBV |
|---|---|---|
| Revenue growthi | 47.70% | 10.20% |
| Earnings growthi | 26.20% | 290.40% |
| EPS growthi | +26.20% | +290.40% |
| FCF margini | +13.89% | +26.20% |
| Operating margini | 54.22% | 40.03% |
| Profit margini | 33.53% | 9.80% |
| ROIC proxyi | 102.29% | 6225.00% |
| Return on equityi | 102.29% | 6225.00% |
| Dividend yieldi | 0.59% | 2.69% |
| Payout ratioi | 21.69% | 190.40% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.51 | 0.28 |
| Debt/equityi | 162.07 | 4789.60 |
| Current ratioi | 1.35 | 0.81 |
| Quick ratioi | 0.68 | 0.49 |
Over the past year, LLY and ABBV have moved weakly in the same direction (correlation of 0.40), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | LLY | ABBV |
|---|---|---|---|
| 1Y | Growthi | +65.61% | +20.96% |
| CAGRi | +65.73% | +20.99% | |
| Volatilityi | 35.64% | 26.39% | |
| Sharpe ratioi | 1.47 | 0.68 | |
| Sortino ratioi | 2.52 | 1.05 | |
| Max drawdowni | 23.31% | 19.23% | |
| Current drawdowni | 7.57% | 0.61% | |
| Avg drawdowni | 6.66% | 7.66% | |
| Ulcer Indexi | 8.66% | 9.00% | |
| Max daily dropi | 7.79% | 5.20% | |
| Max wkly dropi | 8.60% | 8.49% | |
| 5Y | Growthi | +442.38% | +183.51% |
| CAGRi | +40.28% | +23.20% | |
| Volatilityi | 32.74% | 23.36% | |
| Sharpe ratioi | 1.06 | 0.82 | |
| Sortino ratioi | 1.64 | 1.15 | |
| Max drawdowni | 34.48% | 21.92% | |
| Current drawdowni | 7.57% | 0.61% | |
| Avg drawdowni | 7.42% | 8.02% | |
| Ulcer Indexi | 10.22% | 9.97% | |
| Max daily dropi | 14.14% | 12.57% | |
| Max wkly dropi | 17.93% | 17.30% | |
| 10Y | Growthi | +1625.70% | +498.08% |
| CAGRi | +32.96% | +19.59% | |
| Volatilityi | 30.54% | 26.01% | |
| Sharpe ratioi | 0.94 | 0.65 | |
| Sortino ratioi | 1.46 | 0.90 | |
| Max drawdowni | 34.48% | 45.09% | |
| Current drawdowni | 7.57% | 0.61% | |
| Avg drawdowni | 6.97% | 11.51% | |
| Ulcer Indexi | 9.34% | 15.56% | |
| Max daily dropi | 14.14% | 16.25% | |
| Max wkly dropi | 17.93% | 19.39% |
| Category | LLY | ABBV |
|---|---|---|
| Company | Eli Lilly and Company | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Global pharmaceutical company leading the GLP-1 revolution with Mounjaro (tirzepatide) for diabetes and Zepbound for obesity. Also developing treatments in Alzheimer's, oncology, and immunology. | Global biopharmaceutical company with leading positions in immunology (Skyrizi, Rinvoq), aesthetics (Botox, Juvederm), neuroscience, oncology, and eye care. Navigating the Humira biosimilar transition. |
| Investor focus | Mounjaro/Zepbound prescription growth, manufacturing capacity expansion, obesity market penetration, Alzheimer's drug (donanemab) commercial launch, and pipeline depth. | Skyrizi and Rinvoq growth trajectory post-Humira, aesthetics recovery, neuroscience pipeline, dividend sustainability, and revenue diversification beyond immunology. |
- Market-leading GLP-1 franchise — Mounjaro and Zepbound are the fastest-growing drug brands in pharma history
- Obesity represents a massive TAM expansion — tens of millions of potential patients beyond the diabetes population
- Strong pipeline with donanemab (Alzheimer's), oncology assets, and next-generation oral GLP-1 formulations
- Skyrizi and Rinvoq are successfully replacing Humira revenue with combined peak sales potentially exceeding Humira's peak
- Diversified revenue across immunology, aesthetics (Allergan), neuroscience, and oncology provides stability
- Strong dividend with high yield — AbbVie is a Dividend Aristocrat with a commitment to growing its payout
- Premium valuation (highest P/E among large-cap pharma) requires sustained GLP-1 demand and supply execution
- Manufacturing capacity constraints for tirzepatide — scaling production to meet demand is a multi-year challenge
- GLP-1 competition from Novo Nordisk (semaglutide) and emerging oral GLP-1 players could pressure market share
- Humira biosimilar erosion continues — Skyrizi and Rinvoq must grow fast enough to offset the decline
- Aesthetics market (Botox, Juvederm) has been softer than expected due to consumer spending headwinds
- Patent cliffs on key drugs create ongoing need for pipeline replenishment through R&D and M&A
Compare more than two at a time
This page is a fixed writeup on LLY and ABBV. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside LLY and ABBV, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.